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Abstract
High expression of circulating plasma vascular endo-
thelial growth factor (VEGF) in patients with cancer is
an indicator of poor treatment response. Similarly,
hypoxia in tumors, as measured by oxygen needle
electrodes, has been found to predict for tumor-
treatment failure. These two predictors may be related
because hypoxia is a potent stimulator of VEGF
expression in vitro. However, the demonstration of a
relationship between hypoxia and VEGF in human
tumors has, to date, been indirect or even negative.
The purpose of this study was to test whether this
unexpected result was caused by factors unique to
human tumors, or whether the prior results could
have been influenced by the known complexities of
VEGF regulation. Therefore, we undertook a direct
assessment of VEGF induction in human tumors
using in situ hybridization and compared its distribu-
tion with that of hypoxia, as measured by the
distribution of adducts of the hypoxia marker EF5.
The distribution of both markers was assessed in
relationship to the distribution of blood vessels, as
measured by antibodies to CD31. Our hypothesis was
that VEGF mRNA and hypoxia would colocalize,
assuming that detectability of the former was not
limiting. Four squamous cell carcinomas, three sarco-
mas and one glioblastoma multiforme were studied.
When VEGF mRNA signal was detectable, its maxima
colocalized with regional maxima of EF5 binding. The
strongest levels of both signals were sometimes
adjacent to regions of tissue necrosis. However, we
were unable to predict absolute levels of EF5 binding
based on absolute levels of VEGF mRNA. Conversely,
for all tumors studied, regions with relatively low
levels of EF5 binding had relatively low or undetect-
able VEGF mRNA. We found moderate EF5 binding in
some keratinized cells but VEGF mRNA was not
expressed by these differentiated cells. The paradigm
that hypoxia and VEGF expression are linked in
human tumors is supported by the data presented
herein. A better understanding of the biology behind
VEGF expression, including its modulation by hypo-
xia, is important for optimizing its use as a prognostic
indicator and/or modulating its presence with biologic
therapies. Neoplasia (2001) 3, 500–508.
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Introduction
The relationship between hypoxia and treatment outcome in
human cancer has been the subject of intensive investigation
in recent years. Studies using polarographic needle electro-
des to measure tumor oxygenation have shown correlations
between low intratumoral pO2 and poor response to treat-
ment in several tumor types [1–4]. Although the dependence
of radiation killing on cellular oxygenation is well studied [5],
the association between tumor oxygenation and metastasis
or recurrence is less clear. Two paradigms to explain these
observations have been proposed. The first is that hypoxia
causes genetic instability [6 ], which allows selection for a
more aggressive tumor phenotype [7]. The second is that
hypoxia modulates specific cytokines, which are involved in
tumor progression. The best -studied cytokines are those
involved in tumor angiogenesis because tumor growth and
metastasis are dependent on this process [8]. Several of
these cytokines are modulated by tissue oxygenation and are
referred to as oxygen-regulated proteins (ORPs) [9 ]. In
human tumors, vascular endothelial growth factor (VEGF) is
the most commonly expressed cytokine of this group. It is a
potent endothelial mitogen and angiogenic growth factor in
vivo [10]. VEGF also increases capillary leakiness and was
first identified as vascular permeability factor [11]. Despite
the problems of antigen stability, receptor–complex forma-
tion, and sample processing, several studies have shown that
higher level of circulating VEGF protein is an indicator of poor
patient prognosis (see Jelkman for review [12] ). Infact, high
levels of intratumoral VEGF have already been shown to
correlate with poor prognosis in many human tumor types
including squamous cell carcinoma (SCC) [13,14], node-
negative breast carcinoma [15], pancreatic cancer [16],
gastric carcinoma [17], and colon cancer [18]. However,
such conclusions are not universally applicable [19].
Based on in vitro studies, hypoxia is a potent stimulator of
VEGF expression in both human and rodent cell lines
[11,20,21]. In multicellular spheroids, the colocalization of
VEGF mRNA and binding of the hypoxia marker, EF5, has
been demonstrated [22], providing support for the predicted
relationship between VEGF expression and hypoxia. How-
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ever, there are minimal in vivo data on this subject. Most
available in vivo data are based on studies of animals
exposed to a hypoxic environment with VEGF measure-
ments in normal or sometimes tumor tissues ( for example
see Ref. [23] ). Rosmorduc et al. [24] reported the
colocalization of VEGF and binding of the hypoxia marker
pimonidazole in experimental liver fibrogenesis. In situ
hybridization ( ISH) experiments performed on human
tumors have shown that VEGF mRNA is localized to the
cells adjacent to areas of necrosis, which are presumed to
contain the most hypoxic cells [25]. In contrast, Raleigh et al.
[26] found no correlation between the colocalization or levels
of pimonidazole binding and VEGF protein staining in
human SCCs. Similarly, Parliament et al. [27] found that
regions of severe hypoxia in glioma xenografts (as
measured by binding of another hypoxia marker,
[ 3H]misonidazole) did not correspond to areas of VEGF
protein or mRNA expression. Danielson and Rofstad [28]
have concluded that endogenous expression levels of VEGF
are more biologically important than induction by hypoxia.
These studies brought the role of hypoxia regulation of VEGF
expression in human cancers into question. To further
elucidate this matter, we studied binding of EF5 (using
immunohistochemical [ IHC] detection of drug–tissue
adducts) as a surrogate for hypoxia and VEGF mRNA
(using ISH) in human tumors.
The tumors described herein were from a group of
patients participating in a phase I study to determine whether
EF5 could be used safely as a hypoxia marker [29,30]. In the
phase I study design, it was possible to determine the
maximum possible EF5 binding by the tumor tissue. EF5
binding is maximal under severely hypoxic conditions
( <0.005% oxygen) and decreases with increasing oxygen
concentration over the entire physiological range [31]. Our
results show that in tumor tissues where the VEGF mRNA
signal is easily detectable, there is colocalization with
regional maxima of EF5 binding. This occurred in all tumors
where EF5 binding was at least 25% of the maximum
possible binding. Conversely, no VEGF mRNA signal was
found in regions of EF5 binding less than 5% of maximum.
Based on in vitro calibration studies, the oxygen levels
corresponding to these two thresholds are roughly <0.5%
and >3% oxygen, respectively. At intermediate EF5 binding
levels, there was much more heterogeneity of VEGF mRNA
signal. Thus, considering all tumors, absolute levels of VEGF
signal were only roughly correlated with absolute levels of
EF5 binding.
Materials and Methods
Human Subjects
In February 1998 EF5 was granted IND status for use in
human patients with cancer by the FDA and the phase I
protocol was approved by the University of Pennsylvania
Institutional Review Board and the Cancer Therapy Evalua-
tion Program (CTEP) of the National Cancer Institute (NCI).
Written informed consent was obtained from all patients
entered. Eligible patients were those of all ethnic and gender
groups undergoing incisional or excisional tumor biopsies for
other medical indications. Exclusion criteria emphasized a
history of grade III or IV peripheral neuropathy as defined by
the NCI/DCTDC because neurotoxicity has previously been
a problem in the studies of 2-nitroimidazole compounds
used in high, multiple doses as hypoxic cell sensitizers [32].
Pregnant patients, patients less than 18 years of age and
those who were HIV positive were excluded. A subgroup of
the patients on the phase I study was selected for the current
study based on tissue availability, varying histologic tissue
types and tumor locations, and with the goal of studying
tumors of both high and low EF5 binding [29,30]. Our goal
was to determine whether ISH for VEGF would be observed
in sections from these tumors. This staining needed to be in a
region with identifiable morphologic landmarks to compare
with IHC staining for EF5 and CD31 ( to mark blood vessels)
in adjacent or nearly adjacent sections. This was necessary
because the procedures for ISH are not compatible with
those for IHC staining.
Drug Administration
EF5 was supplied by the NCI Division of Cancer Treat-
ment (NCI /DCT) in 100-ml vials containing 3 mg/ml EF5
with solvent composed of water containing 5% dextrose and
2.5% alcohol. EF5 was administered intravenously with a
peripheral intravenous catheter at a rate no greater than
350 ml /hour. The intravenous infusion was over 1 to 2 hours
with time of administration determined by the dose of EF5
being studied. Pharmacokinetic studies of EF5’s plasma
clearance indicated an average biologic half - life of about 12
hours [33]. Binding of EF5 is expected to vary inversely with
tissue oxygen concentration and directly with tissue drug
exposure [34]. Thus, measured binding (see below) was
corrected for total drug exposure or area under the curve
(AUC).
Tissue Acquisition and Storage, ISH, IHC Staining for EF5
Binding, and Other Markers
Surgical excisions often involve tissue devitalization (and,
therefore, hypoxia induction) for variable amounts of time.
Thus, it was considered important to have surgical biopsy or
excision after most circulating drug was cleared and we
chose a time of roughly 48 hours ( range 40 to 55) following
commencement of drug administration when the circulating
drug would have decreased 16- fold, based on its 12-hour
plasma half - life. The procedures for tissue storage, EF5
immunohistochemistry, fluorescence microscopy, and anal-
ysis of binding have been previously reported [29]. Briefly,
tissues were placed on moist filter paper, coated with a thin
layer of Tissue Tek (OCT compound, Sakura Finetek USA
Inc., Torrance, CA), frozen on dry ice, and held at 658C
before sectioning.
In situ hybridization Single-stranded RNA probes were
generated using a 517-bp human VEGF121 cDNA cloned
into a pBluescript KS vector (kindly provided by Dr. H. Marti ).
The plasmid DNA was purified with a Maxiprep kit (Promega,
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Madison, WI). The construct was linearized with BamHI or
EcoRI and transcribed in vitro from the T7 or T3 polymerase
to yield the antisense or sense (control ) probes, respec-
tively. The base sequence of the plasmid DNA was
confirmed by sequence analysis (DNA Sequencing Facility,
Cancer Center, University of Pennsylvania). Transcription
reactions were performed using the Maxiscript in vitro RNA
transcription kit (Ambion, Austin, TX). The transcription
reaction was carried out in the presence of 4 mM
digoxigenin-UTP (Boehringer Mannheim, Indianapolis, IN)
to yield the labeled probe.
Section pretreatment was performed as previously
described [35]. Briefly, tissue was brought from 658 to
208, cut in 10-m sections and placed onto poly-L -
lysine–coated slides. Frozen sections were fixed in 4%
paraformaldehyde, rinsed, dehydrated through graded
ethanols, and stored at 658 until use before hybridization,
sections were brought to room temperature, rehydrated,
permeabilized with Pronase (120 g/ml) for 10 minutes at
room temperature, placed in 0.2% glycine for 30 seconds at
room temperature, placed in acetic anhydride (1:400
dilution in triethanolamine) for 10 minutes, and dehydrated
through graded ethanols. Hybridization and color develop-
ment were carried out as previously described [36] with
minor modifications. Slides were prehybridized in hybrid-
ization buffer for 1 hour at 608 in a humidified chamber.
Hybridization was carried out for 12 to 24 hours at 608 in a
humidified chamber using 4 g/ml of probe in hybridization
buffer. Sections were then digested with RNAse A (20 g/
ml) and washed two times for 15 minutes in 2 SSC, 0.1%
SDS (1 SSC is 0.3 M NaCl plus 0.03 M sodium citrate,
pH 7.0) followed by two washes for 30 minutes in 0.1 SSC
and 0.1% SDS at 558C.
The signal was detected with an alkaline phosphatase
color reaction using anti–digoxigenin antibody coupled to
alkaline phosphatase (Boehringer Mannheim). Slides were
pretreated in buffer 1 (0.1 M maleic acid, 0.1 M NaCl, pH
7.5) then blocked in buffer 2 (2% blocking reagent
(Boehringer Mannheim) with 100 g/ml tRNA, 50 g/ml
heparin) for 30 minutes. Antibody was applied in a 1:500
dilution in buffer 2 for 30 minutes at room temperature.
Excess antibody was removed by two 20-minute rinses in
buffer 1 and the color developed by incubating slides in buffer
3 (100 mM Tris–HCl pH 9.5, 50 mM MgCl2, 2 mM
levamisole) containing 0.338 mg/ml 4-nitroblue tetrazolium
chloride (NBT) and 0.173 mg/ml 5-bromo 4-chloro 3-
indolyl -phosphate (BCIP) for 16 to 18 hours in the dark. The
reaction was stopped in TE buffer (10 mM Tris–HCl, 1 mM
EDTA) for 5 minutes.
Controls for endogenous alkaline phosphatase activity
were performed by treating the samples with chromogen
alone. Sense strand probes were used as a control for
nonspecific binding. Samples known to express VEGF were
used for positive controls.
Two independent observers reviewed the ISH sense and
antisense images and graded the signal of the antisense
images on a scale of 0 to 4: 0 (no staining), 1 ( light brown
staining observable in scattered cells using microscope), 2
( regionally defined light brown staining observable by
microscope), 3 ( regionally defined medium brown staining,
with intensity gradients observable, visible by eye), 4 (dense
brown or purplish-brown, color and intensity gradients,
easily visible by eye).
Digital microscopy The ISH (and hematoxylin and eosin)
slides were photographed using an RGB-ELE liquid crystal
color filter (Cambridge Research and Instrumentation,
Cambridge, MA) in conjunction with the digital camera
(described below). Because of the large images required for
color photography, the regions imaged were identified by
best contrast of the ISH stain and with tissue landmarks
(holes, necrotic areas, edges) that could be applied to find
the same areas for EF5 and CD31 stains in adjacent or
nearly adjacent sections. It was necessary to compare
adjacent tissue sections because the processing for ISH and
immunohistochemistry were incompatible.
Immunohistochemistry Frozen tissue sections were made at
10 m, fixed, blocked, and stained with ELK3-51 antibody
(75 g/ml) conjugated with Cy3 dye. Epifluorescence
measurements were made using a Nikon LabPhot micro-
scope (Melville, NY) with 100-W high-pressure mercury arc
lamp attached to a cooled (258 ) CCD digital camera
(Photometrics Quantix, KF1400, Photometrics, Tucson,
AZ). The manual stage of the microscope was replaced by
a Ludl Electronic Products 99S000 (Hawthorne, NY)
automatic stage with 0.1-m step size. The camera and
stage were controlled by a Macintosh 9600 Power PC
computer (Apple Computer Inc., Cupertino, CA). Software
was Scanalytics ‘‘IP Lab’’ (Scanalytics, Inc., Fairfax, VA) a
general -purpose image analysis program with modular
support of the hardware components. Manual or semi-
automatic scanning of the section, setting of camera
exposure and focus, and automatic collection of images
over a defined area with known positional coordinates were
performed using software written in IP Lab macro code.
Known positional coordinates allowed reimaging of the same
portion of a section after additional staining (e.g., CD31,
hematoxylin and eosin). The regions were imaged using a
10 microscope objective ( field size set electronically at
1.080.72 mm2) and typically 33 contiguous fields were
examined for each section, overlapping a 22 field imaged
for ISH. The resulting images were then aligned (sometimes
with rotation) and cropped using Adobe Photoshop (Adobe
Systems, Inc., San Jose, CA).
IHC staining for CD31/PECAM: Some tissue sections
were stained first for CD31 and subsequently for EF5 to
determine the spatial relationship between hypoxia and
blood vessel distribution. A protocol allowing primary staining
by a mouse monoclonal to human CD31 followed by labeled
secondary rat anti–mouse antibody was used. The secon-
dary antibody labeling allowed detection by peroxidase stain
or fluorescence. Because subsequent staining with mouse
monoclonal antibodies against EF5 adducts would disrupt
the rat anti -mouse secondary labeling for CD31, a short
fixation step was added (4% paraformaldehyde, 20 min. at
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room temperature) before standard rinsing, blocking and
staining for EF5 adducts.
Quantitation of EF5 Staining Intensities
Our previous papers have described the quantitative aspects
of measuring total EF5 adducts by a calibrated fluorescence
detection system [37,38]. In brief, the optical aspects of the
fluorescence microscopy are calibrated with a reference
concentration of fluorescent dye. EF5 binding depends
directly on tissue drug exposure, so this is accounted for
by measuring the drug pharmacokinetics. The maximum
possible binding rate for the specific tissue of interest is
determined by ‘‘cube-reference’’ binding, wherein small
tumor tissue pieces are incubated with EF5 or a closely
related analogue (EF3) under conditions of severe hypoxia
in vitro [29,37,38]. This allows EF5 binding to be monitored
as an absolute value (dependent on the calibrated fluo-
rescence) or as a percentage of cube- reference binding. To
determine the oxygen dependence of binding, we assume
the average oxygen dependence of adduct formation
determined from multiple cell lines in tissue culture [38]. A
rule of thumb estimate for the oxygen dependence of EF5
binding is that it is maximal for pO2 below 0.1%, decreases
inversely with increasing oxygen pO2 (by a factor of 30 to
100) between 0.1% and 10% oxygen and then remains
constant above 10% oxygen.
Nonspecific Staining
Because tumor tissue cannot be collected before treatment
with EF5, we have devised a method to test for the specificity
of observed EF5 binding to allow a measurement of the
‘‘background’’ signal that would result from (minor) non-
specific binding by the detecting antibodies. This procedure
is termed ‘‘competed stain’’ and is accomplished by mixing
EF5 with the antibody before application to the tissue
section. The EF5 blocks all specific binding sites of the
antibody. In animal and tissue culture studies, we have
shown that this method provides an accurate measure of
what the antibody signal would have been for control
conditions ( i.e., without administration of EF5) [38].
Results
The goal of our studies was to evaluate patterns and
intensities of VEGF mRNA and to compare these with EF5
binding at the same spatial location in a sampling of tumors,
using pattern and semiquantitative analyses. Eight tumors
were examined with ISH for VEGF mRNA and immunohis-
tochemistry of EF5 binding for hypoxia (Table 1). These
tumors were selected based on varying histology (soft tissue
sarcomas [STS], SCCs, and glioblastoma multiforme
[GBM]); site (cervix and head and neck for SCC; trunkal,
gastrointestinal and extremity for STS); and EF5 binding
level (a range of values). For the SCC tumors, both
moderate and well -differentiated tumors were selected. A
nondifferentiated SCC was not available for study.
The independent observers agreed on the level of VEGF
mRNA signal in six of the eight samples, and in the other two
samples (patients #1 and #27) they disagreed by one level.
For these two samples, the average of the two scores was
accepted. Four tumors were SCCs, three arising in the
retromolar triangle (patients #5, #7, #26) and one arising in
the uterine cervix (patient #1). VEGF mRNA staining was
strongly positive in sections from two of these tumors
(patients #1, #5); For sections from the cervical cancer
(patient #1), VEGF staining was quite widespread, with local
Table 1. Tumor Information.
Patient # Tumor Site /Histology Stage /Grade EF5 Binding,*
Regional
Maximum
EF5 Binding,* %
Cube Reference
VEGF mRNAy Keratinization? Colocalizationz
1 Cervix /SCC T1BNOMO 47.3 13 3.5 Yes, but not the same
areas as EF5 binding
+
5 Retromolar triangle /SCC T2N2M0 76.9 26 2 Yes, but not the same
areas as EF5 binding
+
7 Retromolar triangle /SCC T4N1M0 75.6 15 0 Yes, same area as
maximal EF5 binding
0
10 Extremity / leiomyosarcoma High grade 190.2 91 4 No +
12 Large bowel / spindle cell SA High grade 36.5 15 1 No IND
16 Trunkal / synovial cell SA High grade 132.6 25 4 No +
26 Retromolar triangle /SCC T4N0M0 41.1 6 0 Yes, same area as
maximal EF5 binding
0
27 Brain /GBM Recurrent 81.9 17 1.5 No IND
SCC, Squamous cell carcinoma, GBM, gliobastoma multiforme, SA, sarcoma.
*EF5 binding is measured on an absolute fluorescence scale, which can then be compared to the maximum possible binding using the cube - reference technique
( see Materials and Methods section ).
yApproximate scale of VEGF mRNA staining: 0 (no staining ), 1 ( light brown staining observable in scattered cells using microscope ), 2 ( regionally defined light
brown staining observable by microscope ), 3 ( regionally defined medium brown staining, with intensity gradients observable, visible by eye ), 4 ( dense brown or
purplish - brown, color and intensity gradients, easily visible by eye ).
zThere is an interaction between the level of VEGF staining, and the ability to determine how closely the two stains colocalize. Thus, a simple ( + ) is used to
indicate that the patterns of observed binding were the same, (0 ) no VEGF signal, ( IND ) not possible to determine due to technical limitations, and (  ) a negative
correlation ( not observed to date ).
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maxima corresponding to local regional maxima of EF5
(Figure 1 ). In contrast, VEGF binding in sections from
patient #5 was localized exclusively to regions containing
regional maxima of EF5 binding (Figure 2 ). Tissues from
patients #7 and #26 hadmoderate to well -differentiated SCC
and showed no detectable VEGFmRNA signal. Because the
fluorescence signal for IHC stain of EF5 has a large dynamic
range ( factor of100) it was possible to discern gradients of
EF5 binding in virtually all tumors. For patient #26, the
highest regional maxima of EF5 binding ( though only 6% of
cube- reference binding) was present in terminally differ-
entiated keratinized tissue (Figure 3 ). This does not involve
a staining artifact, because the competed-stain controls
were negative. Additionally, counterstaining of these tissues
with antibodies to CD31/PECAM demonstrated an inverse
localization between EF5 binding in keratinized cells and
blood vessels (Figure 3 ). This relationship has been a
general observation for human tumors previously studied
( i.e., that EF5 binding almost always increases as a function
of distance from nearest blood vessel [29,30] ).
All three sarcoma tumors (patients #10, #12, #16) were
positive for VEGF mRNA. For the two tumors with strong
VEGF staining (patients #10 and #16) colocalization with
regional maxima in EF5 binding was found (Figure 4 ). For
Figure 2. EF5 IHC, VEGF mRNA antisense, hematoxylin and eosin, and
VEGFmRNA sense staining patterns in a retromolar triangle SCC from patient
#5. EF5 staining and ISH techniques were performed as described in the text.
The sections for EF5, VEGFmRNA sense and antisense were nearly adjacent
to each other. The section for ISH was counterstained for hematoxylin and
eosin. (A ) Moderately differentiated head and neck SCC stained for EF5.
Regions of bright binding are seen adjacent to regions of necrosis (N ). (B )
Moderate signal for VEGF mRNA antisense are seen in cellular regions that
correspond to the brightest areas of EF5 binding. The circle in the center of the
figure is a bubble artifact. (C ) Hematoxylin and eosin demonstrates that the
tissues that stain for EF5 and VEGF mRNA antisense are viable tumor tissue.
The regions that are more eosinophilic ( pink ) are stromal tumor tissue. (D )
Staining for VEGF mRNA with the sense probe reveals no signal. Black region
at 3 o’clock is an artifact. Bar=500 .
Figure 3. EF5 IHC, VEGF mRNA antisense, hematoxylin and eosin, and
CD31 /PECAM versus EF5 patterns in a retromolar triangle SCC from patient
#26. EF5, CD31 staining, and ISH techniques were performed as described in
the text. Sections probed for EF5 and antisense VEGF mRNA were adjacent
to each other. Sections for CD31 /EF5 were from the same tissue mass and
counterstained with hematoxylin and eosin. (A ) Regions of bright EF5 binding
are seen in keratinized (K ) as well as nonkeratinized ( nk ) tumor tissues. A
region of necrosis (N ) is seen adjacent to regions of high EF5 binding. (B )
VEGF mRNA signal is not seen in this tissue. Keratin pearls (K ) are easily
identified. (C ) Hematoxylin and eosin staining demonstrates complex
pathologic patterns in these SCC tumors. Keratin pearls (K ) and nonkerati-
nized tumor tissue and tumor stroma are all identified. (D ) Staining for both
EF5 ( red ) and CD31 (green ) demonstrates the inverse anatomic relationship
between keratinized tumor regions that bind EF5 and blood vessels. This
relationship supports the hypothesis that these keratinized tumor tissues are
hypoxic. Bar=500 .
Figure 1. EF5 IHC and VEGF mRNA antisense staining patterns in a cervical
SCC tumor from patient #1. EF5 staining and ISH techniques were performed
as described in the text. The two sections were significantly displaced from
each other ( approximately 200 m). Thus, the patterns and location of the
highly invaginated and corded structures are similar but not identical. (A )
Regions of high EF5 fluorescent intensity are seen adjacent to regions of
necrosis (N ). (B ) Strong VEGF mRNA intensity is seen in the cellular regions
that correspond to the brightest areas of EF5 binding. Bar=500 .
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sections from the third patient of the sarcoma group (patient
#12) VEGF binding was too weak to adequately capture
digitally. Thus it was not possible to determine colocalization
patterns with EF5.
The recurrent GBM (patient #27) had extensive necrosis,
moderate EF5 binding, and moderate levels of VEGF mRNA
staining. However, both types of binding were scattered
throughout the tumor, often confined to individual cells or
small groups of cells. Because this patient had been
extensively pretreated, this pattern was most likely secon-
dary to the radiation- induced changes present (vascular
hyalinization; necrosis). Due to the scattered nature of the
binding, it was not possible to determine whether the same
cells stained for both VEGF and EF5 (data not shown).
For all of the tumors studied, background EF5 staining
was not observed in slides treated by the competed-stain
method or without antibody (data not shown). Similarly,
background labeling was not observed in slides stained
without VEGF probe and very minimal background staining
was seen with the sense probe (Figures 2 and 4 ). Thus, it is
important to note that all tumor specimens contained regions
with low EF5 binding and no VEGF staining. This prompted
the consideration of whether there was an overall relation-
ship between observable VEGF staining and EF5 binding.
The two measures of EF5 binding (both of which sample the
maximum binding, presumably reflecting minimum oxygen
levels) were absolute binding and percent cube-reference
binding (see Table 1). A plot of VEGF stain intensity versus
percent cube-reference EF5 binding results in a reasonable
correlation with r value of 0.6 (Figure 5 ).
Discussion
Studies exploring the relationship between pro-angiogenic
cytokines such as VEGF and hypoxic tumor regions have
generally relied on indirect measures of tumor hypoxia, i.e.,
VEGF signal in cellular regions distant from blood vessels
and/or close to necrosis have been assumed to be hypoxic
( for example see Ref. [21] ). However, hypoxia is only one of
several pathophysiologic processes that may cause cell
death or regions of high vascularity. For example, necrosis
may be due to the absence of nutrients other than oxygen,
such as glucose [39]. Regions of high vascularity may be
hypoxic if the blood in the vessels is not well oxygenated [40]
although it is generally assumed that high blood vessel
densities imply a high degree of oxygenation. The recent
availability of hypoxia markers that are safe for adminis-
tration to humans [26,29] has allowed more specific and
detailed analysis of the relationship between hypoxia and
VEGF signal. The work reported herein has employed the 2-
nitroimidazole EF5 for hypoxia detection based partially on
previous studies of VEGF mRNA and EF5 colocalization in
HT29 and EMT6 spheroids [22]. In that study, as well as
herein, expression of VEGF mRNA colocalized with regional
maxima in EF5 binding.
Figure 5. Relationship between observed degree of VEGF mRNA signal
(measured by ISH ) and EF5 binding (measured by IHC staining, and
assessed as a percentage of cube - reference binding ).
Figure 4. EF5 IHC, VEGF mRNA antisense and sense staining patterns in a
high -grade synovial cell sarcoma from patient #16. EF5 staining and ISH
techniques were performed as described in the text. The two sections were
adjacent to each other. (A ) High VEGF mRNA signal is seen in an ‘‘H’’ -
shaped region adjacent to areas of necrosis. (B ) Regions of bright EF5
binding are seen, representing hypoxia and these correspond to the VEGF
mRNA signal seen in Figure 3C. In the middle of both areas of EF5 binding,
acellular regions are seen, representing microscopic areas of necrosis (N ).
(C ) VEGF mRNA sense staining pattern corresponding to region of strongest
VEGF antisense signal. Peroxidase staining is not seen, providing a negative
control for comparison. Bar=500 .
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Studies measuring VEGF protein by immunohistochem-
istry have been more controversial. Mouse liver has been
found to bind pimonidazole and produce VEGF protein [24].
However, studies by Parliament et al. [27] suggest a lack of
correlation between VEGF protein expression and the
hypoxia marker, misonidazole, in human tumor xenografts.
Similarly, Raleigh et al. [26] reported that in human SCC,
pimonidazole labeling was adjacent to areas of necrosis,
whereas VEGF protein staining tended to be distant from
regions of necrosis. The differences between these studies
and our findings may relate to differences in the hypoxia-
detection agent used (Pimonidazole or misonidazole vs.
EF5), detection modalities, the endpoint measured for VEGF
(protein vs. mRNA), analysis methods or the patient
population studied. Although similar in the overall mecha-
nism of their bioreduction and binding processes, EF5 and
pimonidazole differ in substantive ways. For example,
because of the equilibrium of different physical–chemical
states of pimonidazole, its biodistribution may depend
strongly on local pH and it has several types of non–oxygen
dependent metabolism [33,41]. However, the former is
unlikely to be the explanation for the lack of correlation seen
in the SCC patients analyzed for binding of pimonidazole
because VEGF has been reported to be upregulated by
acidic microenvironments [42].
EF5 is the only hypoxia marker in current use where
absolute levels of binding are being assessed. Although this
adds complexity to the analysis, it is intriguing that the
highest levels of VEGF RNA expression were only found to
be associated with the highest levels of EF5 binding ( i.e.,
>25% of cube reference) (Table 1). To our knowledge, this
is the first time that in situ methods for VEGF detection have
been combined with a hypoxia marker in tumors from human
patients. We chose to study VEGF mRNA, versus protein,
because two of the four VEGF isoforms (VEGF121 and
VEGF165) are secreted and freely diffusible [43]. Thus, we
hypothesized that VEGF mRNA, rather than protein, would
more likely be colocalized with hypoxia. Support of this
hypothesis would therefore confirm, in human tumors, the
upregulation of VEGF by hypoxia established previously in
model systems.
A synopsis of the four possible patterns of signal from
EF5 binding versus VEGF mRNA induction is presented in
Table 2. When VEGF mRNA staining was high, it typically
localized to regional maxima in EF5 binding ( tumors 5,
10, 16, with 27 possible). Conversely, in regions where
EF5 binding was very low ( <5% of cube reference) no
VEGF signal was detected. Using the calibrated scale of
EF5 binding, we can estimate that such low levels of
binding would be found at partial pressures greater than
3% oxygen. Areas with such low levels of EF5 binding
and lack of VEGF mRNA staining were present in all
tumors examined and can be observed in all figures
described herein. This result was not expected because
factors other than hypoxia can upregulate VEGF signal
[44]. The third possible pattern would be that of VEGF
+ve and EF5 binding ve. The cervix tumor studied
(patient #1, Figure 1 ) provided an example that was
closest to this possibility because it had relatively low EF5
binding, but high expression of VEGF mRNA. However,
the highest levels of VEGF expression still corresponded
to regional maxima in EF5 binding and these areas were
localized adjacent to regions of necrosis (Figure 1 ). We
have hypothesized that necrosis in tumors like this ( i.e.,
without severe hypoxia) might be due to a lack of a
nutrient other than oxygen, for example glucose [29].
Lack of glucose has been shown to induce VEGF in
multicellular spheroids [45] and it is possible that
hypoglycemic stress led to the induction of VEGF in the
tumor of patient #1. Alternatively, the moderate hypoxia in
this tumor may have been sufficient to cause induction of
VEGF mRNA. The fourth possible pattern of staining is
that regions of relatively high EF5 binding could occur
without measurable upregulation of the VEGF signal; two
well -differentiated SCCs showed this pattern ( tumors #7
and #26). Of course, the whole point of defining a scale
of absolute binding is to avoid terms such as ‘‘relatively
high’’ and because the signal:noise ratio of EF5 adduct
detection is very high, almost all tumors can be imaged
with demonstrable gradients of EF5 binding. Thus, for
both of these tumors the maximum EF5 fluorescence was
much less than 25% of maximum, and furthermore the
regional maximal binding occurred almost exclusively in
keratinizing cells that were distant from blood vessels
(Figure 3 ). We have demonstrated that EF5 binding in
these terminally differentiated cells is due neither to
autofluorescence nor to nonspecific staining by the anti-
body, as unstained sections and sections stained with
competed stain (antibody mixed with authentic soluble
antigen — see Materials and Methods section) show
essentially no fluorescence in these areas [29]. The
conclusion that this binding is hypoxia dependent is
supported by the inverse localization of blood vessels
and hypoxic keratinization (Figure 3 ). We suggest the
possibility that hypoxic keratinized cells do not induce
VEGF production because of their differentiated state.
This is supported by studies from Eisma et al. [46]
wherein poorly differentiated SCC cells stained more
intensely for VEGF protein than did well -differentiated
cells [46]. In terms of tumor therapy response, the role of
hypoxic keratinized cells is unknown. It seems likely that
they would have little influence. Thus, if hypoxia is
considered a negative prognostic indictor, it may be
necessary to ensure that the hypoxia signal is not
emanating from terminally differentiated cells. An advant-
age of IHC studies is that they allow the investigation of such
Table 2. Summary of the Histologic Relationship between Patterns of EF5
Binding and VEGF mRNA Expression in Human Tumors.
VEGF+ VEGF
EF5+ Viable hypoxic cells Keratinized cells or
VEGF signal too low
to detect
EF5 Not detected in
this study
Cells oxic or dead
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questions through counterstaining by standard hematoxylin
and eosin techniques. This would not be possible for
electrode measurements or noninvasive assays of binding
by hypoxic markers. Although VEGF ISH signal was not
found in the keratinizing, moderately hypoxic cells, we do not
have an example where the EF5 staining was greater than
25% of cube-reference binding in these cells. One problem
with VEGF ISH signal is its relative difficulty in detection. Not
only is the ISH technique much more time consuming than
routine IHC staining, but the dynamic range of the signal is
quite small. The maximal values appear to vary in a tissue-
specific way, undoubtedly due to other factors involved with
its regulation. This may be a problem of probe specificity,
assay sensitivity or RNA stability of the frozen tissue and we
are presently investigating some of these possibilities.
The results reported herein demonstrate that in all tumors
that were highly positive for VEGF, the VEGF mRNA signal
pattern was coincident with the hypoxia signal from EF5
binding. There have been numerous previous studies
evaluating the relationship among the factors of hypoxia,
ORPs and outcome. Although these factors may be
interrelated, it is not clear that their relationships are limited
to a causal sequence, e.g., that hypoxia leads to upregula-
tion of ORPs, which then results in a poor prognosis. In
specific tumors one or the other factor may be important or
they may be independent factors for prognosis. Future work
will address more detailed studies of these possibilities in a
larger number of patients. However, we have clearly
demonstrated in this report that human tumors upregulate
VEGF mRNA by hypoxia.
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